Skip to main content

Advertisement

SpringerLink
Log in

Medically Managed Hypercholesterolemia and Insulin-Dependent Diabetes Mellitus Preoperatively Predicts Poor Survival after Surgery for Pancreatic Cancer

  • 2010 SSAT Quick Shot Presentation
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Introduction

Although patients with pancreatic ductal adenocarcinoma (PDAC) frequently require medications to treat pre-existing conditions, the impact of these treatments on outcomes post-resection is unknown. The purpose of this study was to determine the impact of preoperative medications on overall survival after pancreatic resection.

Methods

Multi-institutional data on preoperative medications and outcomes in patients undergoing resection for PDAC were analyzed. Univariate and multivariate analyses were performed to determine which medications were predictive of early mortality.

Results

Of the 518 patients resected for PDAC, 13.3% were being treated preoperatively with insulin, 14.8% were on a statin, 1.7% were on steroids, and 7.6% were on thyroxin. On univariate analysis, patients taking preoperative insulin had a higher 90-day mortality rate relative to those not on insulin (13.0% vs. 4.8%, p = 0.024), and those on a statin had a higher 90-day mortality than those who were not (10.8% vs. 4.6%, p = 0.035). Preoperative steroids and thyroxin were not associated with 90-day mortality (p = 0.409 and p = 0.474, respectively). Insulin and statin use was a stronger predictor of 90-day mortality than history of diabetes (p = 0.101), BMI ≥ 30 (p = 0.166), cardiac disease (p = 0.168), pulmonary disease (p = 1.000), or renal dysfunction (p = 1.000). Older patients also had a higher risk of early postoperative death (p = 0.011). On multivariate analysis, only preoperative insulin usage and statin treatment independently predicted early mortality (odds ratio (OR) = 3.043; 95% confidence interval (CI), 1.256–7.372; p = 0.014, and OR = 2.529; 95% CI, 1.048–6.104; p = 0.039, respectively). Based on the beta coefficients, a simple scoring system was devised to predict survival after resection from preoperative medication use. Zero points were assigned to patients who were on neither insulin nor a statin, one point to those who were on one or the other, and two points to those who were on both insulin and a statin. The score correlated with early postoperative survival (90-day mortality rates of 3.4%, 11.5%, and 13.3% for 0, 1, and 2 points, respectively, p = 0.004). Increasing score was also associated with poorer long-term outcomes, with a median overall survival of 19.6, 15.6, and 11.2 months for 0, 1, and 2 points, respectively (p = 0.002, median follow-up 14.4 months).

Conclusions

Patients with PDAC being treated for pre-existing diabetes or hypercholesterolemia with either insulin or statin-based therapy have an increased risk of early postoperative mortality. A simple scoring system based on preoperative medications can be used to predict early and overall survival following resection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology 2008 Jan;134:95-101.

    Article  PubMed  CAS  Google Scholar 

  2. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008 Apr;134:981-987.

    Article  PubMed  CAS  Google Scholar 

  3. Everhart J, Wright D. (1995) Diabetes mellitus as a risk factor for pancreatic cancer A meta-analysis. JAMA 273:1605-1609.

    Article  PubMed  CAS  Google Scholar 

  4. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005 Jun 6;92:2076-2083.

    Article  PubMed  CAS  Google Scholar 

  5. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008 Dec 17;300:2754-2764.

    Article  PubMed  CAS  Google Scholar 

  6. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009 Aug;137:482-488.

    Article  PubMed  Google Scholar 

  7. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 2009 Jun 24;301:2553-2562.

    Article  PubMed  CAS  Google Scholar 

  8. Goldstein MR, Mascitelli L, Pezzetta F. Do statins prevent or promote cancer? Curr Oncol 2008 Apr;15:76-77.

    Article  PubMed  Google Scholar 

  9. Chu CK, Mazo AE, Sarmiento JM, Staley CA, Adsay NV, Umpierrez GE, et al. Impact of diabetes mellitus on perioperative outcomes after resection for pancreatic adenocarcinoma. J Am Coll Surg 2010 Apr;210:463-473.

    Article  PubMed  Google Scholar 

  10. Ramos M, Khalpey Z, Lipsitz S, Steinberg J, Panizales MT, Zinner M, et al. Relationship of perioperative hyperglycemia and postoperative infections in patients who undergo general and vascular surgery. Ann Surg 2008 Oct;248:585-591.

    PubMed  Google Scholar 

  11. Neumayer L, Hosokawa P, Itani K, El-Tamer M, Henderson WG, Khuri SF. Multivariable predictors of postoperative surgical site infection after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg 2007 Jun;204:1178-1187.

    Article  PubMed  Google Scholar 

  12. Frisch A, Chandra P, Smiley D, Peng L, Rizzo M, Gatcliffe C, et al. Prevalence and Clinical Outcome of Hyperglycemia in the Perioperative in non-Cardiac Surgery. Diabetes Care 2010 Aug;33(8):1783–1788.

    Article  PubMed  CAS  Google Scholar 

  13. Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CW, Jr. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 1998 Aug;9:403-410.

    Article  PubMed  CAS  Google Scholar 

  14. Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000 May 17;283:2552-2558.

    Article  PubMed  CAS  Google Scholar 

  15. Chu CK, Mazo AE, Goodman M, Egnatashvili V, Sarmiento JM, Staley CA, et al. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol 2010 Feb;17:502-513.

    Article  PubMed  Google Scholar 

  16. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995 Feb;16:3-34.

    PubMed  CAS  Google Scholar 

  17. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007 May;132:2208-2225.

    Article  PubMed  CAS  Google Scholar 

  18. Call R, Grimsley M, Cadwallader L, Cialone L, Hill M, Hreish V, et al. Insulin--carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research. Postgrad Med 2010 May;122:158-165.

    Article  PubMed  Google Scholar 

  19. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, Bucana CD, et al. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 2003 Sep;163:1001-1011.

    Article  PubMed  CAS  Google Scholar 

  20. Rensing KL, Houttuijn Bloemendaal FM, Weijers EM, Richel DJ, Buller HR, Koolwijk P, et al. Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis? Diabetologia 2010 May;53:966-970.

    Article  PubMed  CAS  Google Scholar 

  21. Basso D, Plebani M, Fogar P, Panozzo MP, Meggiato T, De Paoli M, et al. Insulin-like growth factor-I, interleukin-1 alpha and beta in pancreatic cancer: role in tumor invasiveness and associated diabetes. Int J Clin Lab Res 1995;25:40-43.

    Article  PubMed  CAS  Google Scholar 

  22. Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001 Jan 15;61:589-593.

    PubMed  CAS  Google Scholar 

  23. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996 Feb 29;334:574-579.

    Article  PubMed  CAS  Google Scholar 

  24. Yang YX. Do diabetes drugs modify the risk of pancreatic cancer? Gastroenterology 2009 Aug;137:412-415.

    Google Scholar 

  25. Schneider MB, Matsuzaki H, Haorah J, Ulrich A, Standop J, Ding XZ, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001 Apr;120:1263-1270.

    Article  PubMed  CAS  Google Scholar 

  26. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006 Nov 1;66:10269-10273.

    Article  PubMed  CAS  Google Scholar 

  27. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001 Oct;108:1167-1174.

    PubMed  CAS  Google Scholar 

  28. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007 Feb;9:218-224.

    Article  PubMed  CAS  Google Scholar 

  29. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005 Apr 29;18:283-293.

    Article  PubMed  CAS  Google Scholar 

  30. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006 Feb;29:254-258.

    Article  PubMed  Google Scholar 

  31. Bowker SL, Yasui Y, Veugelers P, Johnson JA. (2010) Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia 53:1631–1637

    Article  PubMed  CAS  Google Scholar 

  32. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005 Jun 4;330:1304-1305.

    Article  PubMed  Google Scholar 

  33. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009 Sep;52:1766-1777.

    Article  PubMed  CAS  Google Scholar 

  34. Batty GD, Kivimaki M, Morrison D, Huxley R, Smith GD, Clarke R, et al. Risk factors for pancreatic cancer mortality: extended follow-up of the original Whitehall Study. Cancer Epidemiol Biomarkers Prev 2009 Feb;18:673-675.

    Article  PubMed  Google Scholar 

  35. Gbelcova H, Lenicek M, Zelenka J, Knejzlik Z, Dvorakova G, Zadinova M, et al. Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer 2008 Mar 15;122:1214-1221.

    Article  PubMed  CAS  Google Scholar 

  36. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005 Apr 20;114:643-647.

    Article  PubMed  CAS  Google Scholar 

  37. Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med 2008 Apr;121:302-309.

    Article  PubMed  CAS  Google Scholar 

  38. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer 2008 Oct;44:2122-2132.

    Article  PubMed  CAS  Google Scholar 

  39. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006 Jan 4;295:74-80.

    Article  PubMed  CAS  Google Scholar 

  40. Bonovas S, Sitaras NM. Does pravastatin promote cancer in elderly patients? A meta-analysis. CMAJ 2007 Feb 27;176:649-654.

    Article  PubMed  Google Scholar 

  41. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 Nov 23;360:1623-1630.

    Article  PubMed  CAS  Google Scholar 

  42. Bonovas S, Filioussi K, Sitaras NM. Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies. Am J Gastroenterol 2008 Oct;103:2646-2651.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Surgery, University of Western Ontario, London, ON, Canada

    Ryaz B. Chagpar

  2. Division of Surgical Oncology, Department of Surgery, University of Louisville, James Graham Brown Cancer Center, Louisville, KY, 40292, USA

    Robert C. G. Martin, Andrew Ebelhar, Juliana Gilbert, Kelly M. McMasters & Charles R. Scoggins

  3. Surgery, University of Cincinnati, Cincinnati, OH, USA

    Syed A. Ahmad

  4. Surgery, University of Wisconsin, Madison, WI, USA

    Sharon Weber, Adam Brinkman, Emily Winslow & Clifford S. Cho

  5. Surgery, University of North Carolina, Chapel Hill, NC, USA

    Hong Jin Kim & Christopher Rupp

  6. Surgery, Emory University, Atlanta, GA, USA

    David Kooby, Carrie K. Chu & Charles A. Staley

Authors
  1. Ryaz B. Chagpar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert C. G. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Syed A. Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hong Jin Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher Rupp
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sharon Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrew Ebelhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Juliana Gilbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Adam Brinkman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Emily Winslow
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Clifford S. Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. David Kooby
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Carrie K. Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Charles A. Staley
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Kelly M. McMasters
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Charles R. Scoggins
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles R. Scoggins.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chagpar, R.B., Martin, R.C.G., Ahmad, S.A. et al. Medically Managed Hypercholesterolemia and Insulin-Dependent Diabetes Mellitus Preoperatively Predicts Poor Survival after Surgery for Pancreatic Cancer. J Gastrointest Surg 15, 551–557 (2011). https://doi.org/10.1007/s11605-011-1448-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-011-1448-3

Keywords

Search

Navigation